An integrative test strategy for cancer hazard identification

Critical Reviews in Toxicology

Volumn 46, Issue 7, 2016, Pages 615-639

  Luijten, Mirjam ^a   Olthof, Evelyn D ^a   Hakkert, Betty C ^a   Rorije, Emiel ^a   van der Laan, Jan Willem ^b   Woutersen, Ruud A ^c   van Benthem, Jan ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c TNO   (Netherlands)

Author keywords

Carcinogenicity; chromosome aberration; DNA damage; genotoxic carcinogens; genotoxicity; mutagenicity; non genotoxic carcinogens; regulatory implementation; risk assessment

Indexed keywords

CARCINOGEN; MUTAGENIC AGENT;

BIOASSAY; CARCINOGEN TESTING; CARCINOGENICITY; GENOTOXICITY; GENOTOXICITY ASSAY; HAZARD ASSESSMENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PHARMACOKINETICS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; TRANSGENIC MOUSE; ANIMAL; DNA DAMAGE; MUTAGEN TESTING; NEOPLASM; PROCEDURES; RISK ASSESSMENT; STANDARDS;

ANIMALS; BIOLOGICAL ASSAY; CARCINOGENICITY TESTS; CARCINOGENS; DNA DAMAGE; HUMANS; MUTAGENICITY TESTS; MUTAGENS; NEOPLASMS; RISK ASSESSMENT;

EID: 84965047091     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2016.1171294     Document Type: Review

References (240)

1. M.J.Aardema, B.B.Barnett, G.C.Mun, E.L.Dahl, R.D.Curren, N.J.Hewitt, S.Pfuhler. 2013. Evaluation of chemicals requiring metabolic activation in the EpiDerm 3D human reconstructed skin micronucleus (RSMN) assay. Mutat Res. 750:40–49.
2. Accelrys DS TOPKAT Software. (2015). [cited 2015 April 7]. Available from: http://accelrys.com/products/datasheets/qsaradmet-and-predicitive-toxicology-with-ds.pdf.
3. S.Adler, D.Basketter, S.Creton, O.Pelkonen, J.van Benthem, V.Zuang, K.E.Andersen, A.Angers-Loustau, A.Aptula, A.Bal-Price,. 2011. Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. Arch Toxicol. 85:367–485.
4. R.H.Alison, C.C.Capen, D.E.Prentice 1994. Neoplastic lesions of questionable significance to humans. Toxicol Pathol. 22:179–186.
5. D.G.Allen, G.Pearse, J.K.Haseman, R.R.Maronpot 2004. Prediction of rodent carcinogenesis: an evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol Pathol. 32:393–401.
6. Z.Ament, C.L.Waterman, J.A.West, C.Waterfield, R.A.Currie, J.Wright, J.L.Griffin. 2013. A metabolomics investigation of non-genotoxic carcinogenicity in the rat. J Proteome Res. 12:5775–5790.
7. B.N.Ames, L.S.Gold 1990. Chemical carcinogenesis: too many rodent carcinogens. Proc Natl Acad Sci USA. 87:7772–7776.
8. G.T.Ankley, R.S.Bennett, R.J.Erickson, D.J.Hoff, M.W.Hornung, R.D.Johnson, D.R.Mount, J.W.Nichols, C.L.Russom, P.K.Schmieder,. 2010. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem. 29:730–741.
9. E.Annys, R.Billington, R.Clayton, K.D.Bremm, M.Graziano, J.McKelvie, I.Ragan, M.Schwarz, L.van derJ.W.aan, C.Wood,. 2014. Advancing the 3Rs in regulatory toxicology – carcinogenicity testing: scope for harmonisation and advancing the 3Rs in regulated sectors of the European Union. Regul Toxicol Pharmacol. 69:234–242.
10. P.Armitage, R.Doll 1954. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer. 8:1–12.
11. J.Ashby, R.W.Tennant 1991. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat Res. 257:229–306.
12. R.Benigni, C.Bossa, O.Tcheremenskaia 2013. Nongenotoxic carcinogenicity of chemicals: mechanisms of action and early recognition through a new set of structural alerts. Chem Rev. 113:2940–2957.
13. I.Berenblum, P.Shubik 1947. The role of croton oil applications, associated with a single painting of a carcinogen, in tumour induction of the mouse's skin. Br J Cancer. 1:379–382.
14. J.G.Bessems, G.Loizou, K.Krishnan, H.J.Clewell3rd, C.Bernasconi, F.Bois, S.Coecke, E.M.Collnot, W.Diembeck, L.R.Farcal,. 2014. PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA–EURL ECVAM ADME workshop. Regul Toxicol Pharmacol. 68:119–139.
15. L.A.Beyer, B.D.Beck, T.A.Lewandowski 2011. Historical perspective on the use of animal bioassays to predict carcinogenicity: evolution in design and recognition of utility. Crit Rev Toxicol. 41:321–338.
16. R.Billington, R.W.Lewis, J.M.Mehta, I.Dewhurst 2010. The mouse carcinogenicity study is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides. Crit Rev Toxicol. 40:35–49.
17. N.Billinton, S.Bruce, J.R.Hansen, P.W.Hastwell, C.Jagger, C.McComb, M.L.Klug, K.Pant, A.Rabinowitz, R.Rees,. 2010. A pre-validation transferability study of the GreenScreen HC GADD45a-GFP assay with a metabolic activation system (S9). Mutat Res. 700:44–50.
18. N.Billinton, P.W.Hastwell, D.Beerens, L.Birrell, P.Ellis, S.Maskell, T.W.Webster, S.Windebank, F.Woestenborghs, A.M.Lynch,. 2008. Interlaboratory assessment of the GreenScreen HC GADD45a-GFP genotoxicity screening assay: an enabling study for independent validation as an alternative method. Mutat Res. 653:23–33.
19. L.Birrell, P.Cahill, C.Hughes, M.Tate, R.M.Walmsley 2010. GADD45a-GFP GreenScreen HC assay results for the ECVAM recommended lists of genotoxic and non-genotoxic chemicals for assessment of new genotoxicity tests. Mutat Res. 695:87–95.
20. B.J.Blaauboer, K.Boekelheide, H.J.Clewell, M.Daneshian, M.M.Dingemans, A.M.Goldberg, M.Heneweer, J.Jaworska, N.I.Kramer, M.Leist,. 2012. The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. Altex. 29:411–425.
21. A.R.Boobis, S.M.Cohen, V.Dellarco, D.McGregor, M.E.Meek, C.Vickers, D.Willcocks, W.Farland. 2006. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol. 36:781–792.
22. A.R.Boobis, S.M.Cohen, N.G.Doerrer, S.M.Galloway, P.J.Haley, G.C.Hard, F.G.Hess, J.S.Macdonald, S.Thibault, D.C.Wolf,. 2009a. A data-based assessment of alternative strategies for identification of potential human cancer hazards. Toxicol Pathol. 37:714–732.
23. A.R.Boobis, G.P.Daston, R.J.Preston, S.S.Olin 2009b. Application of key events analysis to chemical carcinogens and noncarcinogens. Crit Rev Food Sci Nutr. 49:690–707.
24. A.R.Boobis, J.E.Doe, B.Heinrich-Hirsch, M.E.Meek, S.Munn, M.Ruchirawat, J.Schlatter, J.Seed, C.Vickers. 2008. IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev Toxicol. 38:87–96.
25. T.Bourcier, T.McGovern, L.Stavitskaya, N.Kruhlak, D.Jacobson-Kram 2015. Improving prediction of carcinogenicity to reduce, refine, and replace the use of experimental animals. J Am Assoc Lab Anim Sci. 54:163–169.
26. D.R.Boverhof, M.P.Chamberlain, C.R.Elcombe, F.J.Gonzalez, R.H.Heflich, L.G.Hernandez, A.C.Jacobs, D.Jacobson-Kram, M.Luijten, A.Maggi,. 2011. Transgenic animal models in toxicology: historical perspectives and future outlook. Toxicol Sci. 121:207–233.
27. S.Brendler-Schwaab, A.Hartmann, S.Pfuhler, G.Speit 2005. The in vivo comet assay: use and status in genotoxicity testing. Mutagenesis. 20:245–254.
28. R.L.Brent 2015. Protection of the gametes embryo/fetus from prenatal radiation exposure. Health Phys. 108:242–274.
29. S.M.Bryce, S.L.Avlasevich, J.C.Bemis, M.Tate, R.M.Walmsley, F.Saad, K.Van Dijck, M.De Boeck, F.Van Goethem, M.Lukamowicz-Rajska,. 2013. Flow cytometric 96-well microplate-based in vitro micronucleus assay with human TK6 cells: protocol optimization and transferability assessment. Environ Mol Mutagen. 54:180–194.
30. J.K.Buick, I.Moffat, A.Williams, C.D.Swartz, L.Recio, D.R.Hyduke, H.H.Li, A.J.J.FornaceAJ, Jr., J.Aubrecht, C.L.Yauk. 2015. Integration of metabolic activation with a predictive toxicogenomics signature to classify genotoxic versus nongenotoxic chemicals in human TK6 cells. Environ Mol Mutagen. 56:520–534.
31. X.Cao, R.A.Mittelstaedt, M.G.Pearce, B.C.Allen, L.G.Soeteman-Hernandez, G.E.Johnson, C.A.Bigger, R.H.Heflich. 2014. Quantitative dose-response analysis of ethyl methanesulfonate genotoxicity in adult gpt-delta transgenic mice. Environ Mol Mutagen. 55:385–399.
32. N.Carmichael, M.Bausen, A.R.Boobis, S.M.Cohen, M.Embry, C.Fruijtier-Polloth, H.Greim, R.Lewis, M.E.Bette Meek, H.Mellor,. 2011. Using mode of action information to improve regulatory decision-making: an ECETOC/ILSI RF/HESI workshop overview. Crit Rev Toxicol. 41:175–186.
33. K.E.Chapman, A.D.Thomas, J.W.Wills, S.Pfuhler, S.H.Doak, G.J.Jenkins 2014. Automation and validation of micronucleus detection in the 3D EpiDerm™ human reconstructed skin assay and correlation with 2D dose responses. Mutagenesis. 29:165–175.
34. H.J.Clewell, P.R.Gentry, J.M.Gearhart, B.C.Allen, M.E.Andersen 2001. Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. Sci Total Environ. 274:37–66.
35. H.J.Clewell, Y.M.Tan, J.L.Campbell, M.E.Andersen 2008. Quantitative interpretation of human biomonitoring data. Toxicol Appl Pharmacol. 231:122–133.
36. M.J.Clift, D.O.Raemy, C.Endes, Z.Ali, A.D.Lehmann, C.Brandenberger, A.Petri-Fink, P.Wick, W.J.Parak, P.Gehr,. 2013. Can the Ames test provide an insight into nano-object mutagenicity? Investigating the interaction between nano-objects and bacteria. Nanotoxicology. 7:1373–1385.
37. S.Coecke, O.Pelkonen, S.B.Leite, U.Bernauer, J.G.Bessems, F.Y.Bois, U.Gundert-Remy, G.Loizou, E.Testai, J.M.Zaldivar. 2013. Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches. Toxicol In Vitro. 27:1570–1577.
38. S.M.Cohen 1998. Cell proliferation and carcinogenesis. Drug Metab Rev. 30:339–357.
39. S.M.Cohen 2004. Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. Toxicol Sci. 80:225–229.
40. S.M.Cohen 2010. Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: the two-year bioassay is no longer necessary. Toxicol Pathol. 38:487–501.
41. S.M.Cohen, L.B.Ellwein 1991. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res. 51:6493–6505.
42. S.M.Cohen, J.Klaunig, M.E.Meek, R.N.Hill, T.Pastoor, L.Lehman-McKeeman, J.Bucher, D.G.Longfellow, J.Seed, V.Dellarco,. 2004. Evaluating the human relevance of chemically induced animal tumors. Toxicol Sci. 78:181–186.
43. F.Colotta, P.Allavena, A.Sica, C.Garlanda, A.Mantovani 2009. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 30:1073–1081.
44. S.W.Dean, T.M.Brooks, B.Burlinson, J.Mirsalis, B.Myhr, L.Recio, V.Thybaud. 1999. Transgenic mouse mutation assay systems can play an important role in regulatory mutagenicity testing in vivo for the detection of site-of-contact mutagens. Mutagenesis. 14:141–151.
45. I.Decordier, A.Papine, K.Vande Loock, G.Plas, F.Soussaline, M.Kirsch-Volders 2011. Automated image analysis of micronuclei by IMSTAR for biomonitoring. Mutagenesis. 26:163–168.
46. DEREK Nexus. (2015). A knowledge based toxicity prediction tool; [cited 2015 April 7]. Available from: http://www.lhasalimited.org/products/derek-nexus.htm.
47. S.D.Dertinger, S.Phonethepswath, S.L.Avlasevich, D.K.Torous, J.Mereness, S.M.Bryce, J.C.Bemis, S.Bell, P.Weller, J.T.Macgregor. 2012. Efficient monitoring of in vivo pig-a gene mutation and chromosomal damage: summary of 7 published studies and results from 11 new reference compounds. Toxicol Sci. 130:328–348.
48. S.H.Doak, B.Manshian, G.J.Jenkins, N.Singh 2012. In vitro genotoxicity testing strategy for nanomaterials and the adaptation of current OECD guidelines. Mutat Res. 745:104–111.
49. V.N.Dobrovolsky, D.Miura, R.H.Heflich, S.D.Dertinger 2010. The in vivo Pig-a gene mutation assay, a potential tool for regulatory safety assessment. Environ Mol Mutagen. 51:825–835.
50. W.C.Eastin, J.H.Mennear, R.W.Tennant, R.E.Stoll, D.G.Branstetter, J.R.Bucher, B.McCullough, R.L.Binder, J.W.Spalding, J.F.Mahler. 2001. Tg.AC genetically altered mouse: assay working group overview of available data. Toxicol Pathol. 29 Suppl:60–80.
51. D.A.Eastmond, A.Hartwig, D.Anderson, W.A.Anwar, M.C.Cimino, I.Dobrev, G.R.Douglas, T.Nohmi, D.H.Phillips, C.Vickers. 2009. Mutagenicity testing for chemical risk assessment: update of the WHO/IPCS Harmonized Scheme. Mutagenesis. 24:341–349.
52. D.A.Eastmond, S.V.Vulimiri, J.E.French, B.Sonawane 2013. The use of genetically modified mice in cancer risk assessment: challenges and limitations. Crit Rev Toxicol. 43:611–631.
53. EC. (2008). Council Regulation (EC) No 440/2008 of 30 May 2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH). Official Journal L 142:1–739.
54. EC. (2009). Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. Official Journal L 342:59–209.
55. EC. (2013). Commission Regulation (EU) No 284/2013 of 1 March 2013 setting out the data requirements for plant protection products, in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market. Official Journal L 93:85–152.
56. ECHA. (2014). The Use of Alternatives to Testing on Animals for the REACH Regulation. Second report under Article 117(3) of the REACH Regulation. Available from: http://echa.europa.eu/documents/10162/13639/alternatives_test_animals_2014_en.pdf.
57. C.R.Elcombe, J.Odum, J.R.Foster, S.Stone, S.Hasmall, A.R.Soames, I.Kimber, J.Ashby. 2002. Prediction of rodent nongenotoxic carcinogenesis: evaluation of biochemical and tissue changes in rodents following exposure to nine nongenotoxic NTP carcinogens. Environ Health Perspect. 110:363–375.
58. H.Ellinger-Ziegelbauer, J.M.Fostel, C.Aruga, D.Bauer, E.Boitier, S.Deng, D.Dickinson, A.C.Le Fevre, A.J.J.FornaceAJ Jr, O.Grenet,. 2009. Characterization and interlaboratory comparison of a gene expression signature for differentiating genotoxic mechanisms. Toxicol Sci. 110:341–352.
59. H.Ellinger-Ziegelbauer, H.Gmuender, A.Bandenburg, H.J.Ahr 2008. Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. Mutat Res. 637:23–39.
60. H.Ellinger-Ziegelbauer, B.Stuart, B.Wahle, W.Bomann, H.J.Ahr 2005. Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat Res. 575:61–84.
61. EMA (European Medicines Agency). 2012. Guideline on the investigation of drug interactions. London: EMA.
62. E.R.Fearon, B.Vogelstein 1990. A genetic model for colorectal tumorigenesis. Cell. 61:759–767.
63. M.D.Fellows, M.R.O'Donovan 2007. Cytotoxicity in cultured mammalian cells is a function of the method used to estimate it. Mutagenesis. 22:275–280.
64. M.R.Fielden, A.Adai, R.T.Dunn, 2nd, A.Olaharski, G.Searfoss, J.Sina, J.Aubrecht, E.Boitier, P.Nioi, S.Auerbach,. 2011. Development and evaluation of a genomic signature for the prediction and mechanistic assessment of nongenotoxic hepatocarcinogens in the rat. Toxicol Sci. 124:54–74.
65. M.R.Fielden, R.Brennan, J.Gollub 2007. A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol Sci. 99:90–100.
66. N.Fjodorova, M.Vracko, M.Novic, A.Roncaglioni, E.Benfenati 2010. New public QSAR model for carcinogenicity. Chem Cent J. 4:S3.
67. S.Fluckiger-Isler, M.Kamber 2012. Direct comparison of the Ames microplate format (MPF) test in liquid medium with the standard Ames pre-incubation assay on agar plates by use of equivocal to weakly positive test compounds. Mutat Res. 747:36–45.
68. L.Foulds 1954. The experimental study of tumor progression: a review. Cancer Res. 14:327–339.
69. P.Fowler, K.Smith, J.Young, L.Jeffrey, D.Kirkland, S.Pfuhler, P.Carmichael. 2012a. Reduction of misleading (“false”) positive results in mammalian cell genotoxicity assays. I. Choice of cell type. Mutat Res. 742:11–25.
70. P.Fowler, R.Smith, K.Smith, J.Young, L.Jeffrey, P.Carmichael, D.Kirkland, S.Pfuhler. 2014. Reduction of misleading (“false”) positive results in mammalian cell genotoxicity assays. III: sensitivity of human cell types to known genotoxic agents. Mutat Res Genet Toxicol Environ Mutagen. 767:28–36.
71. P.Fowler, R.Smith, K.Smith, J.Young, L.Jeffrey, D.Kirkland, S.Pfuhler, P.Carmichael. 2012b. Reduction of misleading (“false”) positive results in mammalian cell genotoxicity assays. II. Importance of accurate toxicity measurement. Mutat Res. 747:104–117.
72. W.Frieauff, H.J.Martus, W.Suter, A.Elhajouji 2013. Automatic analysis of the micronucleus test in primary human lymphocytes using image analysis. Mutagenesis. 28:15–23.
73. A.Friedrich, K.Olejniczak 2011. Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995–2009). Regul Toxicol Pharmacol. 60:225–248.
74. S.Galloway, E.Lorge, M.J.Aardema, D.Eastmond, M.Fellows, R.Heflich, D.Kirkland, D.D.Levy, A.M.Lynch, D.Marzin,. 2011. Workshop summary: top concentration for in vitro mammalian cell genotoxicity assays; and report from working group on toxicity measures and top concentration for in vitro cytogenetics assays (chromosome aberrations and micronucleus). Mutat Res. 723:77–83.
75. S.M.Galloway 2000. Cytotoxicity and chromosome aberrations in vitro: experience in industry and the case for an upper limit on toxicity in the aberration assay. Environ Mol Mutagen. 35:191–201.
76. D.W.Gaylor 2005. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens? Regul Toxicol Pharmacol. 41:128–133.
77. L.S.Gold, T.H.Slone, B.N.Ames 1998. What do animal cancer tests tell us about human cancer risk?: overview of analyses of the carcinogenic potency database. Drug Metab Rev. 30:359–404.
78. B.B.Gollapudi, G.E.Johnson, L.G.Hernandez, L.H.Pottenger, K.L.Dearfield, A.M.Jeffrey, E.Julien, J.H.Kim, D.P.Lovell, J.T.Macgregor,. 2013. Quantitative approaches for assessing dose-response relationships in genetic toxicology studies. Environ Mol Mutagen. 54:8–18.
79. L.Gonzalez, B.J.Sanderson, M.Kirsch-Volders 2011. Adaptations of the in vitro MN assay for the genotoxicity assessment of nanomaterials. Mutagenesis. 26:185–191.
80. D.J.Gordon, B.Resio, D.Pellman 2012. Causes and consequences of aneuploidy in cancer. Nat Rev Genet. 13:189–203.
81. C.Gotz, N.J.Hewitt, E.Jermann, J.Tigges, Z.Kohne, U.Hubenthal, J.Krutmann, H.F.Merk, E.Fritsche. 2012. Effects of the genotoxic compounds, benzo[a]pyrene and cyclophosphamide on phase 1 and 2 activities in EpiDerm™ models. Xenobiotica. 42:526–537.
82. R.E.Greenfield, L.B.Ellwein, S.M.Cohen 1984. A general probabilistic model of carcinogenesis: analysis of experimental urinary bladder cancer. Carcinogenesis. 5:437–445.
83. S.K.Greenwood, R.B.Hill, J.T.Sun, M.J.Armstrong, T.E.Johnson, J.P.Gara, S.M.Galloway. 2004. Population doubling: a simple and more accurate estimation of cell growth suppression in the in vitro assay for chromosomal aberrations that reduces irrelevant positive results. Environ Mol Mutagen. 43:36–44.
84. D.Gulezian, D.Jacobson-Kram, C.B.McCullough, H.Olson, L.Recio, D.Robinson, R.Storer, R.Tennant, J.M.Ward, D.A.Neumann. 2000. Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment. Toxicol Pathol. 28:482–499.
85. K.Z.Guyton, A.D.Kyle, J.Aubrecht, V.J.Cogliano, D.A.Eastmond, M.Jackson, N.Keshava, M.S.Sandy, B.Sonawane, L.Zhang,. 2009. Improving prediction of chemical carcinogenicity by considering multiple mechanisms and applying toxicogenomic approaches. Mutat Res. 681:230–240.
86. D.Hanahan, R.A.Weinberg 2000. The hallmarks of cancer. Cell. 100:57–70.
87. D.Hanahan, R.A.Weinberg 2011. Hallmarks of cancer: the next generation. Cell. 144:646–674.
88. J.K.Haseman, A.M.Clark 1990. Carcinogenicity results for 114 laboratory animal studies used to assess the predictivity of four in vitro genetic toxicity assays for rodent carcinogenicity. Environ Mol Mutagen. 16:15–31.
89. P.W.Hastwell, L.L.Chai, K.J.Roberts, T.W.Webster, J.S.Harvey, R.W.Rees, R.M.Walmsley. 2006. High-specificity and high-sensitivity genotoxicity assessment in a human cell line: validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. Mutat Res. 607:160–175.
90. P.W.Hastwell, T.W.Webster, M.Tate, N.Billinton, A.M.Lynch, J.S.Harvey, R.W.Rees, R.M.Walmsley. 2009. Analysis of 75 marketed pharmaceuticals using the GADD45a-GFP 'GreenScreen HC' genotoxicity assay. Mutagenesis. 24:455–463.
91. HazardExpert Pro. (2015). [cited 2015 April 7]. Available from: http://www.compudrug.com/hazardexpertpro.
92. G.Hendriks, M.Atallah, B.Morolli, F.Calleja, N.Ras-Verloop, I.Huijskens, M.Raamsman, B.van de Water, H.Vrieling. 2012. The ToxTracker assay: novel GFP reporter systems that provide mechanistic insight into the genotoxic properties of chemicals. Toxicol Sci. 125:285–298.
93. G.Hendriks, M.Atallah, M.Raamsman, B.Morolli, H.van der Putten, H.Jaadar, I.Tijdens, L.Esveldt-vanR.ange, L.Mullenders, B.van de Water,. 2011. Sensitive DsRed fluorescence-based reporter cell systems for genotoxicity and oxidative stress assessment. Mutat Res. 709–710:49–59.
94. G.Hendriks, R.S.Derr, B.Misovic, B.Morolli, F.M.Calleja, H.Vrieling 2015. The extended ToxTracker assay discriminates between induction of DNA damage, oxidative stress and protein misfolding. Toxicol Sci. 150:190–203.
95. L.G.Hernandez, H.van Steeg, M.Luijten, J.van Benthem 2009. Mechanisms of non-genotoxic carcinogens and importance of a weight of evidence approach. Mutat Res. 682:94–109.
96. N.J.Hewitt, R.J.Edwards, E.Fritsche, C.Goebel, P.Aeby, J.Scheel, K.Reisinger, G.Ouedraogo, D.Duche, J.Eilstein,. 2013. Use of human in vitro skin models for accurate and ethical risk assessment: metabolic considerations. Toxicol Sci. 133:209–217.
97. M.P.Holsapple, H.C.Pitot, S.M.Cohen, A.R.Boobis, J.E.Klaunig, T.Pastoor, V.L.Dellarco, Y.P.Dragan. 2006. Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol Sci. 89:51–56.
98. T.Hu, Z.S.Khambatta, P.J.Hayden, J.Bolmarcich, R.L.Binder, M.K.Robinson, G.J.Carr, J.P.Tiesman, B.B.Jarrold, R.Osborne,. 2010. Xenobiotic metabolism gene expression in the EpiDermin vitro 3D human epidermis model compared to human skin. Toxicol In Vitro. 24:1450–1463.
99. S.M.Huang, D.R.Abernethy, Y.Wang, P.Zhao, I.Zineh 2013. The utility of modeling and simulation in drug development and regulatory review. J Pharm Sci. 102:2912–2923.
100. C.Hughes, A.Rabinowitz, M.Tate, L.Birrell, J.Allsup, N.Billinton, R.M.Walmsley. 2012. Development of a high-throughput Gaussia luciferase reporter assay for the activation of the GADD45a gene by mutagens, promutagens, clastogens, and aneugens. J Biomol Screen. 17:1302–1315.
101. ICH. (1995). Guideline S1A: need for carcinogenicity studies of pharmaceuticals. Geneva, Switzerland: ICH.
102. ICH. (1997). Guideline S1B: testing for carcinogenicity of pharmaceuticals. Geneva, Switzerland: ICH.
103. ICH. (2008). Guideline S1C (R2): dose selection for carcinogenicity studies of pharmaceuticals. Geneva, Switzerland: ICH.
104. ICH. (2013). Proposed change to rodent carcinogenicity testing of pharmaceuticals – regulatory notice document. Geneva, Switzerland: ICH.
105. ICH. (2014). Guideline M7: assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. Geneva, Switzerland: ICH.
106. S.Izumi, A.Suyama, K.Koyama 2003. Radiation-related mortality among offspring of atomic bomb survivors: a half-century of follow-up. Int J Cancer. 107:292–297.
107. A.Jacobs 2005. Prediction of 2-year carcinogenicity study results for pharmaceutical products: how are we doing? Toxicol Sci. 88:18–23.
108. A.C.Jacobs, K.P.Hatfield 2013. History of chronic toxicity and animal carcinogenicity studies for pharmaceuticals. Vet Pathol. 50:324–333.
109. D.Jacobson-Kram, F.D.Sistare, A.C.Jacobs 2004. Use of transgenic mice in carcinogenicity hazard assessment. Toxicol Pathol. 32:49–52.
110. G.E.Johnson, L.G.Soeteman-Hernandez, B.B.Gollapudi, O.G.Bodger, K.L.Dearfield, R.H.Heflich, J.G.Hixon, D.P.Lovell, J.T.MacGregor, L.H.Pottenger,. 2014. Derivation of point of departure (PoD) estimates in genetic toxicology studies and their potential applications in risk assessment. Environ Mol Mutagen. 55:609–623.
111. H.M.Jones, I.B.Gardner, K.J.Watson 2009. Modelling and PBPK simulation in drug discovery. AAPS J. 11:155–166.
112. F.J.Jongeneelen, W.F.Berge 2011. A generic, cross-chemical predictive PBTK model with multiple entry routes running as application in MS Excel; design of the model and comparison of predictions with experimental results. Ann Occup Hyg. 55:841–864.
113. M.J.Jonker, O.Bruning, M.van Iterson, M.M.Schaap, T.V.van der Hoeven, H.Vrieling, R.B.Beems, A.de Vries, H.van Steeg, T.M.Breit,. 2009. Finding transcriptomics biomarkers for in vivo identification of (non-)genotoxic carcinogens using wild-type and Xpa/p53 mutant mouse models. Carcinogenesis. 30:1805–1812.
114. S.H.Kang, J.Y.Kwon, J.K.Lee, Y.R.Seo 2013. Recent advances in in vivo genotoxicity testing: prediction of carcinogenic potential using comet and micronucleus assay in animal models. J Cancer Prev. 18:277–288.
115. H.L.Karlsson, A.R.Gliga, F.M.Calleja, C.S.Goncalves, I.O.Wallinder, H.Vrieling, B.Fadeel, G.Hendriks. 2014. Mechanism-based genotoxicity screening of metal oxide nanoparticles using the ToxTracker panel of reporter cell lines. Part Fibre Toxicol. 11:41.
116. M.Karstadt, J.K.Haseman 1997. Effect of discounting certain tumor types/sites on evaluations of carcinogenicity in laboratory animals. Am J Ind Med. 31:485–494.
117. T.Kimoto, S.Chikura, K.Suzuki-Okada, X.M.Kobayashi, Y.Itano, D.Miura, Y.Kasahara. 2012. Effective use of the Pig-a gene mutation assay for mutagenicity screening: measuring CD59-deficient red blood cells in rats treated with genotoxic chemicals. J Toxicol Sci. 37:943–955.
118. K.W.Kinzler, B.Vogelstein 1996. Lessons from hereditary colorectal cancer. Cell. 87:159–170.
119. D.Kirkland, M.Aardema, L.Henderson, L.Muller 2005. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat Res. 584:1–256.
120. D.Kirkland, P.Fowler 2010. Further analysis of Ames-negative rodent carcinogens that are only genotoxic in mammalian cells in vitro at concentrations exceeding 1 mM, including retesting of compounds of concern. Mutagenesis. 25:539–553.
121. D.Kirkland, P.Kasper, L.Muller, R.Corvi, G.Speit 2008. Recommended lists of genotoxic and non-genotoxic chemicals for assessment of the performance of new or improved genotoxicity tests: a follow-up to an ECVAM workshop. Mutat Res. 653:99–108.
122. D.Kirkland, S.Pfuhler, D.Tweats, M.Aardema, R.Corvi, F.Darroudi, A.Elhajouji, H.Glatt, P.Hastwell, M.Hayashi,. 2007. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: report of an ECVAM Workshop. Mutat Res. 628:31–55.
123. D.Kirkland, E.Zeiger, F.Madia, R.Corvi 2014. Can in vitro mammalian cell genotoxicity test results be used to complement positive results in the Ames test and help predict carcinogenic or in vivo genotoxic activity? II. Construction and analysis of a consolidated database. Mutat Res Genet Toxicol Environ Mutagen. 775–776:69–80.
124. M.Kirsch-Volders, I.Decordier, A.Elhajouji, G.Plas, M.J.Aardema, M.Fenech 2011. In vitro genotoxicity testing using the micronucleus assay in cell lines, human lymphocytes and 3D human skin models. Mutagenesis. 26:177–184.
125. J.E.Klaunig, Z.Wang, X.Pu, S.Zhou 2011. Oxidative stress and oxidative damage in chemical carcinogenesis. Toxicol Appl Pharmacol. 254:86–99.
126. A.G.Knudson 2001. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 1:157–162.
127. A.G.KnudsonJr. 1971. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 68:820–823.
128. M.Kodaira, S.Izumi, N.Takahashi, N.Nakamura 2004. No evidence of radiation effect on mutation rates at hypervariable minisatellite loci in the germ cells of atomic bomb survivors. Radiat Res. 162:350–356.
129. I.B.Lambert, T.M.Singer, S.E.Boucher, G.R.Douglas 2005. Detailed review of transgenic rodent mutation assays. Mutat Res. 590:1–280.
130. LeadScope. 2015. Rodent carcinogenicity Suite. QSAR Models. Columbus, OH: LeadScope Inc.
131. H.H.Li, D.R.Hyduke, R.Chen, P.Heard, C.L.Yauk, J.Aubrecht, A.J.J.FornaceAJ Jr. 2015. Development of a toxicogenomics signature for genotoxicity using a dose-optimization and informatics strategy in human cells. Environ Mol Mutagen. 56:505–519.
132. W.Lilienblum, W.Dekant, H.Foth, T.Gebel, J.G.Hengstler, R.Kahl, P.J.Kramer, H.Schweinfurth, K.M.Wollin. 2008. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH). Arch Toxicol. 82:211–236.
133. G.Loizou, A.Hogg 2011. MEGen: a physiologically based pharmacokinetic model generator. Front Pharmacol. 2:56.
134. R.H.Luecke, B.A.Pearce, W.D.Wosilait, D.R.Doerge, W.Slikker, Jr, J.F.Young 2008. Windows based general PBPK/PD modeling software. Comput Biol Med. 38:962–978.
135. A.Maunz, M.Gutlein, M.Rautenberg, D.Vorgrimmler, D.Gebele, C.Helma 2013. lazar: a modular predictive toxicology framework. Front Pharmacol. 4:38. doi:10.3389/fphar.2013.00038.
136. M.E.Meek, A.Boobis, I.Cote, V.Dellarco, G.Fotakis, S.Munn, J.Seed, C.Vickers. 2014a. New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. J Appl Toxicol. 34:1–18.
137. M.E.Meek, J.R.Bucher, S.M.Cohen, V.Dellarco, R.N.Hill, L.D.Lehman-McKeeman, D.G.Longfellow, T.Pastoor, J.Seed, D.E.Patton. 2003. A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol. 33:591–653.
138. M.E.Meek, J.C.Lipscomb 2015. Gaining acceptance for the use of in vitro toxicity assays and QIVIVE in regulatory risk assessment. Toxicology. 332:112–123.
139. M.E.Meek, C.M.Palermo, A.N.Bachman, C.M.North, R.Jeffrey Lewis 2014b. Mode of action human relevance (species concordance) framework: evolution of the Bradford Hill considerations and comparative analysis of weight of evidence. J Appl Toxicol. 34:595–606.
140. J.P.Melis, K.W.Derks, T.E.Pronk, P.Wackers, M.M.Schaap, E.Zwart, W.F.van IJcken, M.J.Jonker, T.M.Breit, J.Pothof,. 2014. In vivo murine hepatic microRNA and mRNA expression signatures predicting the (non-)genotoxic carcinogenic potential of chemicals. Arch Toxicol. 88:1023–1034.
141. J.P.Melis, H.van Steeg, M.Luijten 2013. Oxidative DNA damage and nucleotide excision repair. Antioxid Redox Signal. 18:2409–2419.
142. S.Mena, A.Ortega, J.M.Estrela 2009. Oxidative stress in environmental-induced carcinogenesis. Mutat Res. 674:36–44.
143. I.R.Miousse, R.Currie, K.Datta, H.Ellinger-Ziegelbauer, J.E.French, A.H.Harrill, I.Koturbash, M.Lawton, D.Mann, R.R.Meehan,. 2015. Importance of investigating epigenetic alterations for industry and regulators: an appraisal of current efforts by the Health and Environmental Sciences Institute. Toxicology. 335:11–19.
144. D.Miura, V.N.Dobrovolsky, R.A.Mittelstaedt, Y.Kasahara, Y.Katsuura, R.H.Heflich 2008. Development of an in vivo gene mutation assay using the endogenous Pig-A gene: II. Selection of Pig-A mutant rat spleen T-cells with proaerolysin and sequencing Pig-A cDNA from the mutants. Environ Mol Mutagen. 49:622–630.
145. J.G.Moggs, J.I.Goodman, J.E.Trosko, R.A.Roberts 2004. Epigenetics and cancer: implications for drug discovery and safety assessment. Toxicol Appl Pharmacol. 196:422–430.
146. S.H.Moolgavkar, A.G.KnudsonJr. 1981. Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst. 66:1037–1052.
147. T.Morita, A.Miyajima, A.Hatano, M.Honma 2014. Effects of lowering the proposed top-concentration limit in an in vitro chromosomal aberration test on assay sensitivity and on the reduction of the number of false positives. Mutat Res Genet Toxicol Environ Mutagen. 769:34–49.
148. G.C.Mun, M.J.Aardema, T.Hu, B.Barnett, Y.Kaluzhny, M.Klausner, V.Karetsky, E.L.Dahl, R.D.Curren. 2009. Further development of the EpiDerm 3D reconstructed human skin micronucleus (RSMN) assay. Mutat Res. 673:92–99.
149. MultiCASE Software. (2015). [cited 2015 April 7]. Available from: http://multicase.com/.
150. I.Nestorov 2007. Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol. 3:235–249.
151. NRC (National Research Council). (2007). Toxicity testing in the 21st century: a vision and a strategy. Ontario, Canada: National Research Council.
152. NTP (National Toxicology Program), U.S. Department of Health and Human Services, Public Health Service. (2014). Report on carcinogens. 13th ed. Research Triangle Park, NC: NTP.
153. OECD. (1997a). Test No. 471: bacterial reverse mutation test. Paris, France: OECD.
154. OECD. (1997b). Test No. 476: in vitro mammalian cell gene mutation test. Paris, France: OECD.
155. OECD. (2007). Detailed review paper on cell transformation assays for detection of chemical carcinogens. Series on testing and assessment. Paris, France: OECD Environment, Health and Safety Publications.
156. OECD. (2013a). Guidance document on developing and asssessing adverse outcome pathways. Series on testing and assessment No. 184. Paris, France: OECD Environment, Health and Safety Publications.
157. OECD. (2013b). Test No. 488: transgenic rodent somatic and germ cell gene mutation assays. Paris, France: OECD Publishing.
158. OECD. (2014a). Draft guidance document: in vitro syrian hamster embryo (SHE) cell transformation assay (December 2014). Paris, France: OECD.
159. OECD. (2014b). Draft guidance document: in vitro syrian hamster embryo (SHE) cell transformation assay (July 2014). Paris, France: OECD.
160. OECD. (2014c). Guidance on grouping of chemicals. 2nd ed. Series on Testing and No. 194. Paris, France: OECD Environment, Health and Safety Publications.
161. OECD. (2014d). Test No. 473: in vitro mammalian chromosomal aberration test. Paris, France: OECD Publishing.
162. OECD. (2014e). Test No. 474: mammalian erythrocyte micronucleus test. Paris, France: OECD Publishing.
163. OECD. (2014f). Test No. 475: mammalian bone marrow chromosomal aberration test. Paris, France: OECD Publishing.
164. OECD. (2014g). Test No. 487: in vitro mammalian cell micronucleus test. Paris, France: OECD Publishing.
165. OECD. (2014h). Test No. 489: in vivo mammalian alkaline comet assay. Paris, France: OECD Publishing.
166. OECD. (2015a). Draft guidance document on Bhas 42 cell transformation assay. Paris, France: OECD.
167. OECD. (2015b). QSAR Toolbox; software for grouping chemicals into categories and filling datagaps in (eco)toxicity data needed for assessing the hazard of chemicals. Paris, France: OECD.
168. A.J.Olaharski, S.Albertini, L.Mueller, A.Zeller, M.Struwe, E.Gocke, K.Kolaja. 2011. GADD45α induction in the GreenScreen HC indicator assay does not occur independently of cytotoxicity. Environ Mol Mutagen. 52:28–34.
169. T.G.Osimitz, W.Droege, A.R.Boobis, B.G.Lake 2013. Evaluation of the utility of the lifetime mouse bioassay in the identification of cancer hazards for humans. Food Chem Toxicol. 60:550–562.
170. J.M.Parry, G.J.Jenkins, F.Haddad, R.Bourner, E.M.Parry 2000. In vitro and in vivo extrapolations of genotoxin exposures: consideration of factors which influence dose-response thresholds. Mutat Res. 464:53–63.
171. J.M.Parry, E.Parry, P.Phrakonkham, R.Corvi 2010. Analysis of published data for top concentration considerations in mammalian cell genotoxicity testing. Mutagenesis. 25:531–538.
172. V.Passerini, E.Ozeri-Galai, M.S.de Pagter, N.Donnelly, S.Schmalbrock, W.P.Kloosterman, B.Kerem, Z.Storchova. 2016. The presence of extra chromosomes leads to genomic instability. Nat Commun. 7:10754.
173. T.Pastoor, J.Stevens 2005. Historical perspective of the cancer bioassay. Scand J Work Environ Health. 31:129–140. discussion 119–122.
174. G.Patlewicz, N.Jeliazkova, R.J.Safford, A.P.Worth, B.Aleksiev 2008. An evaluation of the implementation of the Cramer classification scheme in the Toxtree software. SAR QSAR Environ Res. 19:495–524.
175. S.Pfuhler, R.Fautz, G.Ouedraogo, A.Latil, J.Kenny, C.Moore, W.Diembeck, N.J.Hewitt, K.Reisinger, J.Barroso. 2014. The Cosmetics Europe strategy for animal-free genotoxicity testing: project status up-date. Toxicol In Vitro. 28:18–23.
176. S.Pfuhler, D.Kirkland, P.Kasper, M.Hayashi, P.Vanparys, P.Carmichael, S.Dertinger, D.Eastmond, A.Elhajouji, C.Krul,. 2009. Reduction of use of animals in regulatory genotoxicity testing: identification and implementation opportunities-Report from an ECVAM workshop. Mutat Res. 680:31–42.
177. I.P.Pogribny, F.A.Beland 2012. DNA methylome alterations in chemical carcinogenesis. Cancer Lett. 334:39–45.
178. I.P.Pogribny, I.Rusyn 2013. Environmental toxicants, epigenetics, and cancer. Adv Exp Med Biol. 754:215–232.
179. L.H.Pottenger, B.B.Gollapudi 2010. Genotoxicity testing: moving beyond qualitative “screen and bin" approach towards characterization of dose-response and thresholds”. Environ Mol Mutagen. 51:792–799.
180. I.S.Pratt, T.Barron 2003. Regulatory recognition of indirect genotoxicity mechanisms in the European Union. Toxicol Lett. 140–141:53–62.
181. M.V.Reddy, F.D.Sistare, J.S.Christensen, J.G.Deluca, G.K.Wollenberg, J.J.Degeorge 2010. An evaluation of chronic 6- and 12-month rat toxicology studies as predictors of 2-year tumor outcome. Vet Pathol. 47:614–629.
182. G.Reifferscheid, H.M.Maes, B.Allner, J.Badurova, S.Belkin, K.Bluhm, F.Brauer, J.Bressling, S.Domeneghetti, T.Elad,. 2012. International round-robin study on the Ames fluctuation test. Environ Mol Mutagen. 53:185–197.
183. A.A.Reus, K.Reisinger, T.R.Downs, G.J.Carr, A.Zeller, R.Corvi, C.A.Krul, S.Pfuhler. 2013. Comet assay in reconstructed 3D human epidermal skin models-investigation of intra- and inter-laboratory reproducibility with coded chemicals. Mutagenesis. 28:709–720.
184. D.E.Robinson, J.S.MacDonald 2001. Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute. Toxicol Pathol. 29:13–19.
185. M.Romer, J.Eichner, U.Metzger, M.F.Templin, S.Plummer, H.Ellinger-Ziegelbauer, A.Zell. 2014. Cross-platform toxicogenomics for the prediction of non-genotoxic hepatocarcinogenesis in rat. PLoS One. 9:e97640.
186. A.Rossnerova, M.Spatova, C.Schunck, R.J.Sram 2011. Automated scoring of lymphocyte micronuclei by the MetaSystems Metafer image cytometry system and its application in studies of human mutagen sensitivity and biodosimetry of genotoxin exposure. Mutagenesis. 26:169–175.
187. A.Rostami-Hodjegan 2012. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther. 92:50–61.
188. D.M.Rotroff, B.A.Wetmore, D.J.Dix, S.S.Ferguson, H.J.Clewell, K.A.Houck, E.L.Lecluyse, M.E.Andersen, R.S.Judson, C.M.Smith,. 2010. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol Sci. 117:348–58.
189. SCCS. (2015). Notes of Guidance (NoG) for the Testing of Cosmetic Ingredients and their Safety Evaluation, 9th Revision. SCCS/1564/15, 29 September 2015.
190. M.M.Schaap, P.F.Wackers, E.P.Zwart, I.Huijskens, M.J.Jonker, G.Hendriks, T.M.Breit, H.van Steeg, B.van de Water, M.Luijten. 2014. A novel toxicogenomics-based approach to categorize (non-)genotoxic carcinogens. Arch Toxicol. 89:2413–2427.
191. M.M.Schaap, E.P.Zwart, P.F.Wackers, I.Huijskens, B.van de Water, T.M.Breit, H.van Steeg, M.J.Jonker, M.Luijten. 2012. Dissecting modes of action of non-genotoxic carcinogens in primary mouse hepatocytes. Arch Toxicol. 86:1717–1727.
192. A.J.Schetter, N.H.Heegaard, C.C.Harris 2010. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 31:37–49.
193. J.Seed, E.W.Carney, R.A.Corley, K.M.Crofton, J.M.DeSesso, P.M.Foster, R.Kavlock, G.Kimmel, J.Klaunig, M.E.Meek,. 2005. Overview: using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit Rev Toxicol. 35:664–672.
194. B.Silva Lima, J.W.Van der Laan 2000. Mechanisms of nongenotoxic carcinogenesis and assessment of the human hazard. Regul Toxicol Pharmacol. 32:135–143.
195. K.Simpson, N.Bevan, P.Hastwell, P.Eidam, P.Shah, E.Gogo, S.Rees, A.Brown. 2013. The BlueScreen-384 assay as an indicator of genotoxic hazard potential in early-stage drug discovery. J Biomol Screen. 18:441–452.
196. F.D.Sistare, D.Morton, C.Alden, J.Christensen, D.Keller, S.D.Jonghe, R.D.Storer, M.V.Reddy, A.Kraynak, B.Trela,. 2011. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines. Toxicol Pathol. 39:716–744.
197. C.Sonich-Mullin, R.Fielder, J.Wiltse, K.Baetcke, J.Dempsey, P.Fenner-Crisp, D.Grant, M.Hartley, A.Knaap, D.Kroese,. 2001. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul Toxicol Pharmacol. 34:146–152.
198. J.W.Spalding, J.E.French, S.Stasiewicz, M.Furedi-Machacek, F.Conner, R.R.Tice, R.W.Tennant. 2000. Responses of transgenic mouse lines p53(+/−) and Tg.AC to agents tested in conventional carcinogenicity bioassays. Toxicol Sci. 53:213–223.
199. G.Speit, H.Kojima, B.Burlinson, A.R.Collins, P.Kasper, U.Plappert-Helbig, Y.Uno, M.Vasquez, C.Beevers, M.De Boeck,. 2015. Critical issues with the in vivo comet assay: a report of the comet assay working group in the 6th International Workshop on Genotoxicity Testing (IWGT). Mutat Res Genet Toxicol Environ Mutagen. 783:6–12.
200. R.D.Storer, J.E.French, J.Haseman, G.Hajian, E.K.LeGrand, G.G.Long, L.A.Mixson, R.Ochoa, J.E.Sagartz, K.A.Soper. 2001. P53+/- hemizygous knockout mouse: overview of available data. Toxicol Pathol. 29:30–50.
201. G.W.Suter, II, S.M.Cormier 2011. Why and how to combine evidence in environmental assessments: weighing evidence and building cases. Sci Total Environ. 409:1406–1417.
202. R.W.Tennant 1993. Stratification of rodent carcinogenicity bioassay results to reflect relative human hazard. Mutat Res. 286:111–118.
203. R.W.Tennant, B.H.Margolin, M.D.Shelby, E.Zeiger, J.K.Haseman, J.Spalding, W.Caspary, M.Resnick, S.Stasiewicz, B.Anderson,. 1987. Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Science. 236:933–941.
204. R.W.Tennant, J.Spalding 1996. Predictions for the outcome of rodent carcinogenicity bioassays: identification of trans-species carcinogens and noncarcinogens. Environ Health Perspect. 104:1095–1100.
205. R.W.Tennant, J.Spalding, J.E.French 1996. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutat Res. 365:119–127.
206. J.P.Thomson, J.G.Moggs, C.R.Wolf, R.R.Meehan 2014. Epigenetic profiles as defined signatures of xenobiotic exposure. Mutat Res Genet Toxicol Environ Mutagen. 764–765:3–9.
207. R.R.Tice, E.Agurell, D.Anderson, B.Burlinson, A.Hartmann, H.Kobayashi, Y.Miyamae, E.Rojas, J.C.Ryu, Y.F.Sasaki. 2000. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen. 35:206–221.
208. K.E.Tollefsen, S.Scholz, M.T.Cronin, S.W.Edwards, J.de Knecht, K.Crofton, N.Garcia-Reyero, T.Hartung, A.Worth, G.Patlewicz. 2014. Applying adverse outcome pathways (AOPs) to support integrated approaches to testing and assessment (IATA). Regul Toxicol Pharmacol. 70:629–640.
209. T.Uehara, Y.Minowa, Y.Morikawa, C.Kondo, T.Maruyama, I.Kato, N.Nakatsu, Y.Igarashi, A.Ono, H.Hayashi,. 2011. Prediction model of potential hepatocarcinogenicity of rat hepatocarcinogens using a large-scale toxicogenomics database. Toxicol Appl Pharmacol. 255:297–306.
210. Y.Uno, T.Morita, M.Luijten, C.Beevers, S.Hamada, S.Itoh, W.Ohyama, H.Takasawa. 2015a. Micronucleus test in rodent tissues other than liver or erythrocytes: Report of the IWGT working group. Mutat Res Genet Toxicol Environ Mutagen. 783:19–22.
211. Y.Uno, T.Morita, M.Luijten, C.Beevers, S.Hamada, S.Itoh, W.Ohyama, H.Takasawa. 2015b. Recommended protocols for the liver micronucleus test: Report of the IWGT working group. Mutat Res Genet Toxicol Environ Mutagen. 783:13–18.
212. U.S. Environmental Protection Agency. (2005). Guidelines for carcinogen risk assessment. Risk Assessment Forum, Washington, DC. EPA/639/P-03/001F.
213. US FDA (Food and Drug Administration), U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER). (2012). Guidance for Industry. Drug Interaction Studies – Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations.
214. T.Usui, M.Mutai, S.Hisada, M.Takoaka, K.A.Soper, B.McCullough, C.Alden. 2001. CB6F1-rasH2 mouse: overview of available data. Toxicol Pathol. 29:90–108.
215. J.H.van Delft, E.van Agen, S.G.van Breda, M.H.Herwijnen, Y.C.Staal, J.C.Kleinjans 2005. Comparison of supervised clustering methods to discriminate genotoxic from non-genotoxic carcinogens by gene expression profiling. Mutat Res. 575:17–33.
216. J.W.Van der Laan, J.J.DeGeorge, F.D.Sistare, J.G.Moggs 2013. Toward more scientific relevance in carcinogenicity testing. In: J.W.Van der Laan, J.J.DeGeorge, editors. Global approach in safety testing. New York: Springer-Verlag.
217. J.W.Van der Laan, P.Kasper, B.Silva Lima, D.J.Jones, M.Pasanen 2016. Critical analysis of carcinogenicity study outcomes – relation with pharmacological properties. Crit Rev Toxicol. [in press].
218. J.C.van Eijkeren, M.I.Bakker, M.J.Zeilmaker 2006. A simple steady-state model for carry-over of aflatoxins from feed to cow's milk. Food Addit Contam. 23:833–838.
219. C.F.van Kreijl, P.A.McAnulty, R.B.Beems, A.Vynckier, H.van Steeg, R.Fransson-Steen, C.L.Alden, R.Forster, J.W.van der Laan, J.Vandenberghe. 2001. Xpa and Xpa/p53+/- knockout mice: overview of available data. Toxicol Pathol. 29:117–127.
220. J.P.Van Oosterhout, J.W.Van der Laan, E.J.De Waal, K.Olejniczak, M.Hilgenfeld, V.Schmidt, R.Bass. 1997. The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul Toxicol Pharmacol. 25:6–17.
221. M.Z.Vasquez 2012. Recommendations for safety testing with the in vivo comet assay. Mutat Res. 747:142–156.
222. P.Vasseur, C.Lasne 2012. OECD Detailed Review Paper (DRP) number 31 on “Cell Transformation Assays for Detection of Chemical Carcinogens”: main results and conclusions. Mutat Res. 744:8–11.
223. B.Vogelstein, K.W.Kinzler 1993. The multistep nature of cancer. Trends Genet. 9:138–141.
224. R.M.Walmsley, M.Tate 2012. The GADD45a-GFP GreenScreen HC assay. Methods Mol Biol. 817:231–250.
225. T.Watanabe, T.Suzuki, M.Natsume, M.Nakajima, K.Narumi, S.Hamada, T.Sakuma, A.Koeda, K.Oshida, Y.Miyamoto,. 2012. Discrimination of genotoxic and non-genotoxic hepatocarcinogens by statistical analysis based on gene expression profiling in the mouse liver as determined by quantitative real-time PCR. Mutat Res. 747:164–175.
226. M.D.Waters, M.Jackson, I.Lea 2010. Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods. Mutat Res. 705:184–200.
227. B.A.Wetmore 2015. Quantitative in vitro-to-in vivo extrapolation in a high-throughput environment. Toxicology. 332:94–101.
228. B.A.Wetmore, J.F.Wambaugh, S.S.Ferguson, L.Li, H.J.Clewell3rd, R.S.Judson, K.Freeman, W.Bao, M.A.Sochaski, T.M.Chu,. 2013. Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. Toxicol Sci. 132:327–346.
229. J.Whitwell, R.Smith, K.Jenner, H.Lyon, D.Wood, J.Clements, K.Aschcroft-Hawley, B.Gollapudi, D.Kirkland, E.Lorge,. 2015. Relationships between p53 status, apoptosis and induction of micronuclei in different human and mouse cell lines in vitro: implications for improving existing assays. Mutat Res Genet Toxicol Environ Mutagen. 789–790:7–27.
230. WHO (World Health Organization). (2010). Characterization and application of physiologically based pharmacokinetic models in risk assessment, International Programme on Chemical Safety. Geneva, Switzerland: WHO.
231. I.Wilk-Zasadna, C.Bernasconi, O.Pelkonen, S.Coecke 2015. Biotransformation in vitro: an essential consideration in the quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data. Toxicology. 332:8–19.
232. Y.T.Woo, D.Y.Lai 2003. Mechanism of action of chemical carcinogens and their role in structure-activity relationships analysis and risk assessment. In: R.Benigni, editor. Quantitative structure-activity relationship (QSAR) analysis of mutagens and carcinogens. Boca Raton (FL): CRC Press.
233. S.Wu, K.Blackburn, J.Amburgey, J.Jaworska, T.Federle 2010. A framework for using structural, reactivity, metabolic and physicochemical similarity to evaluate the suitability of analogs for SAR-based toxicological assessments. Regul Toxicol Pharmacol. 56:67–81.
234. F.Yamada, K.Sumida, T.Uehara, Y.Morikawa, H.Yamada, T.Urushidani, Y.Ohno. 2013. Toxicogenomics discrimination of potential hepatocarcinogenicity of non-genotoxic compounds in rat liver. J Appl Toxicol. 33:1284–1293.
235. S.Yamamoto, K.Urano, H.Koizumi, S.Wakana, K.Hioki, K.Mitsumori, Y.Kurokawa, Y.Hayashi, T.Nomura. 1998. Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Environ Health Perspect. 106:57–69.
236. C.L.Yauk, M.J.Aardema, J.van Benthem, J.B.Bishop, K.L.Dearfield, D.M.DeMarini, Y.E.Dubrova, M.Honma, J.R.Lupski, F.Marchetti,. 2015. Approaches for identifying germ cell mutagens: report of the 2013 IWGT workshop on germ cell assays(⋆). Mutat Res Genet Toxicol Environ Mutagen. 783:36–54.
237. M.Yoon, J.L.Campbell, M.E.Andersen, H.J.Clewell 2012. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Crit Rev Toxicol. 42:633–652.
238. E.Zeiger 1998. Identification of rodent carcinogens and noncarcinogens using genetic toxicity tests: premises, promises, and performance. Regul Toxicol Pharmacol. 28:85–95.
239. E.Zeiger, J.K.Haseman, M.D.Shelby, B.H.Margolin, R.W.Tennant 1990. Evaluation of four in vitro genetic toxicity tests for predicting rodent carcinogenicity: confirmation of earlier results with 41 additional chemicals. Environ Mol Mutagen. 16:1–14.
240. P.Zhao, L.Zhang, J.A.Grillo, Q.Liu, J.M.Bullock, Y.J.Moon, P.Song, S.S.Brar, R.Madabushi, T.C.Wu,. 2011. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 89:259–267.